A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Name: A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Published: 2015
License: Public Domain

Hoffmann-La Roche · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

multiple-myeloma

multiple myeloma, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Related documents